Commerce Bank Boosts Position in Eli Lilly and Company (NYSE:LLY)

Commerce Bank raised its position in Eli Lilly and Company (NYSE:LLY) by 26.3% during the 4th quarter, Holdings Channel reports. The firm owned 164,214 shares of the company’s stock after acquiring an additional 34,237 shares during the quarter. Eli Lilly and Company comprises about 0.8% of Commerce Bank’s holdings, making the stock its 25th biggest position. Commerce Bank’s holdings in Eli Lilly and Company were worth $126,773,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Highline Wealth Partners LLC raised its position in Eli Lilly and Company by 80.0% during the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company’s stock worth $35,000 after acquiring an additional 20 shares during the last quarter. FPC Investment Advisory Inc. raised its position in shares of Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock worth $45,000 after purchasing an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. purchased a new stake in Eli Lilly and Company in the 4th quarter valued at approximately $48,000. Compass Financial Services Inc acquired a new stake in Eli Lilly and Company during the 4th quarter valued at $50,000. Finally, Fiduciary Advisors Inc. purchased a new position in Eli Lilly and Company during the fourth quarter worth $58,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on LLY. Citigroup decreased their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Morgan Stanley reduced their price objective on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 9th. Guggenheim lowered their target price on shares of Eli Lilly and Company from $973.00 to $928.00 and set a “buy” rating for the company in a research note on Monday. Finally, Wells Fargo & Company raised their price objective on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Two equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,012.00.

Eli Lilly and Company Price Performance

LLY stock opened at $841.70 on Friday. The stock has a 50-day simple moving average of $829.56 and a 200-day simple moving average of $820.64. The firm has a market cap of $798.08 billion, a P/E ratio of 71.88, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.